Your browser doesn't support javascript.
loading
Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.
Harskamp, Ralf E; Lucassen, Wim A M; Lopes, Renato D; Himmelreich, Jelle C L; Parati, Gianfranco; Weert, Henk C P M van.
Afiliação
  • Harskamp RE; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Academic Medical Center, AZ Amsterdam, The Netherlands.
  • Lucassen WAM; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
  • Lopes RD; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Academic Medical Center, AZ Amsterdam, The Netherlands.
  • Himmelreich JCL; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
  • Parati G; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Academic Medical Center, AZ Amsterdam, The Netherlands.
  • Weert HCPMV; IRCCS Instituto Auxologico Italiano and Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Acta Cardiol ; 77(3): 191-195, 2022 May.
Article em En | MEDLINE | ID: mdl-33685380
ABSTRACT
BACKGROUND AND

PURPOSE:

Hypertension is common in patients with atrial fibrillation (AF) and carries an additional risk for complications, most notably stroke and bleeding. We assessed the history of hypertension, level of blood pressure control, and an interaction with the choice of oral anticoagulants on clinical outcomes.

METHODS:

We performed a systematic review and meta-analysis of studies that randomised patients to novel oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) and reported outcomes stratified by presence of hypertension. Collected outcomes were ischaemic stroke or systemic embolism (SE), haemorrhagic stroke, intracranial haemorrhage and major bleeding. Log adjusted hazard ratios (HR) and corresponding standard error were calculated, and HRs were compared using Mantel-Haenszel random effects. Quality of the evidence was assessed with Cochrane risk of bias tool.

RESULTS:

Five high-quality studies were eligible, including 71.527 participants who received NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) or VKAs, with median follow-up of 1.8-2.8 years. Compared with patients without hypertension, those with hypertension had higher adjusted risk for ischaemic stroke/SE (HR 1.25, 95%-CI1.09, 1.43) and haemorrhagic stroke (HR1.98, 1.24-3.16). On a continuous scale, the risk of ischaemic stroke/SE increased 6-7% per 10 mmHg increase in systolic blood pressure. No interactions were found between the efficacy or safety of NOACs versus VKAs in the presence or absence of hypertension. In both groups, the use of NOACs led to a lower risk of ischaemic stroke/SE, haemorrhagic stroke and intracranial haemorrhage compared with patients that used VKAs.

CONCLUSIONS:

Adequate blood pressure management is vital to optimally reduce the risk of stroke in patients with atrial fibrillation. The benefits of NOACs over VKAs, also apply to patients with elevated blood pressure.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Isquemia Encefálica / Acidente Vascular Cerebral / Embolia / AVC Isquêmico / Acidente Vascular Cerebral Hemorrágico / Hipertensão Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Acta Cardiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Isquemia Encefálica / Acidente Vascular Cerebral / Embolia / AVC Isquêmico / Acidente Vascular Cerebral Hemorrágico / Hipertensão Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Acta Cardiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda